טוען...
CTLA4Ig inhibits effector T cells through regulatory T cells and TGFβ()
The CD28 costimulatory receptor is a critical regulator of T cell function making it an attractive therapeutic target for the treatment of immune mediated diseases. CTLA4Ig, now approved for use in humans, prevents naive T cell activation by binding to B7-proteins and blocking engagement of CD28. Ho...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3775269/ https://ncbi.nlm.nih.gov/pubmed/23956428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1300830 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|